Biology subjects

Fjeld, K.

Publications and source records attributed to Fjeld, K..

2 recordsLinked to original sources

bioRxiv2026

ERα-regulated IRX3 controls the growth of ER-positive breast tumors

Estrogen receptor positive (ER+) breast cancer is primarily treated with endocrine therapies targeting ER signaling. Although endocrine therapy has substantially improved survival in ER+ breast cancer, metastatic disease remains largely incurable, underscoring the need to elucidate additional mechanisms driving growth and proliferation. Here, we show that the homeobox protein IRX3 is selectively overexpressed in ER+ breast cancer and define the molecular function of IRX3 in ER+ breast cancer using an integrated combination of in vitro, in vivo and in silico approaches. We uncover a previously uncharacterized distal regulatory region that controls IRX3 transcription via ER and associated steroid receptor coactivators. Consistent with this regulatory axis, anti-estrogen treatment resulted in marked downregulation of cellular IRX3 levels. Functionally, depletion of IRX3 suppresses proliferation of the human ER+ breast cancer cells in vitro, but paradoxically promotes tumor growth and metastatic dissemination in orthotopic xenografts in vivo by stimulating enhanced tumor vascularization. Finally, low tumor expression of IRX3 correlates with poorer survival outcomes in patients with ER+ breast cancer. Collectively, these findings establish IRX3 as an important regulator of ER+ breast tumor biology and reveal an ER-dependent role for IRX3 in modulating proliferative and vascular programs in tumor progression. SignificanceBy identifying a novel ER-dependent regulatory pathway, this work refines our understanding of how hormone signaling shapes both breast tumor growth and the surrounding microenvironment.

cancer biology↗

bioRxiv2020

The position of single-base deletions in the VNTR sequence of the carboxyl ester lipase (CEL) gene determines pathogenicity

Variable number of tandem repeat (VNTR) sequences present in the genome can have functional consequences that contribute to human disease. This is the case for the CEL gene, which encodes the digestive enzyme carboxyl ester lipase. CEL has a VNTR located in exon 11, and rare single-base deletions (DELs) within this region cause MODY8, an inherited disorder characterized by exocrine pancreatic dysfunction and diabetes. Here, we have studied how the position of single-base deletions within the CEL VNTR affects the proteins pathogenic properties. We investigated four naturally occurring CEL variants with single-base deletions in different VNTR segments (DEL1, DEL4, DEL9, DEL13), of which only DEL1 and DEL4 have been observed in MODY8 patients. When expressed in a cellular model system, only DEL1 and DEL4 exhibited significantly reduced secretion and increased intracellular aggregation compared to normal CEL. We found that all DEL variants had slightly decreased enzymatic activity and that their level of O-glycosylation was affected. Moreover, only DEL1 and DEL4 significantly increased endoplasmic reticulum (ER) stress. In conclusion, CEL single-base deletion variants have the highest pathogenic potential when the mutational event has taken place in the proximal VNTR part, resulting in the longest aberrant protein tails. Thus, DEL1 and DEL4 are pathogenic CEL variants, whereas we consider DEL13 as benign and DEL9 as likely benign. These findings have implications for our understanding of how CEL mutations cause pancreatic disease through protein misfolding and proteotoxicity, leading to ER stress and activation of the unfolded protein response.

cell biology↗